公开(公告)号：US20180344850A1

公开(公告)日：2018-12-06

申请号：US15992852

申请日：2018-05-30

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Frederic A. BOURKE, JR. ,  Mark DEWHIRST ,  Neil SPECTOR ,  Paul YOON ,  Justus ADAMSON ,  David ALCORTA ,  Kim LYERLY ,  Leihua LIU ,  Takuya OSADA ,  Mark OLDHAM ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Harold WALDER

IPC: A61K41/00 ,  A61K31/37 ,  A61K45/06 ,  A61K9/00

Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.

公开(公告)号：US20200009398A1

公开(公告)日：2020-01-09

申请号：US16554831

申请日：2019-08-29

Applicant: IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

Inventor： Mark OLDHAM ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Frederic A. BOURKE, JR. ,  Harold WALDER ,  Mark DEWHIRST ,  Neil L. SPECTOR ,  Paul YOON ,  Justus ADAMSON ,  David ALCORTA ,  Kim LYERLY ,  Leihua LIU ,  Takuya OSADA

IPC: A61N5/06 ,  A61K31/352 ,  A61K41/00

Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

公开(公告)号：US20170157418A1

公开(公告)日：2017-06-08

申请号：US15434871

申请日：2017-02-16

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Mark OLDHAM ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Harold WALDER ,  Frederic A. BOURKE, JR. ,  Mark DEWHIRST ,  Neil L. SPECTOR ,  Paul YOON ,  Justus ADAMSON ,  David ALCORTA ,  Kim LYERLY ,  Leihua LIU ,  Takuya OSADA

IPC: A61N5/06 ,  A61K31/352 ,  A61K41/00 ,  A61N5/10

CPC classification number: A61N5/062 ,  A61K31/352 ,  A61K31/525 ,  A61K33/00 ,  A61K35/00 ,  A61K38/00 ,  A61K41/0066 ,  A61N5/10 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1089 ,  A61N2005/1098

Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

公开(公告)号：US20170015758A1

公开(公告)日：2017-01-19

申请号：US15113189

申请日：2015-01-21

Applicant: MEDIMMUNE, LLC ,  DUKE UNIVERSITY

Inventor： Scott A. HAMMOND ,  Michael A. MORSE ,  Takuya OSADA ,  Herbert Kim LYERLY

IPC: C07K16/30 ,  C07K16/28

CPC classification number: C07K16/3007 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/732

Abstract: Provided herein are methods of modulating and redirecting an immune response. Compositions and methods for killing targeted cells in a cell population are also provided wherein, a cell population containing target cells expressing a target associated antigen and T cells are contacted with 1, 2, or more immune checkpoint antagonists and a multispecific T cell-redirecting agent that specifically binds the target associated antigen expressed on the target cells and specifically binds a T cell surface antigen.

Abstract translation: 本文提供了调节和重定向免疫应答的方法。 还提供了用于杀死细胞群体中靶向细胞的组合物和方法，其中将含有表达靶标相关抗原和T细胞的靶细胞的细胞群与1,2或更多免疫检验点拮抗剂和多特异性T细胞重定向剂接触 其特异性结合目标细胞上表达的靶标相关抗原并特异性结合T细胞表面抗原。